Prednisone, lupus activity, and permanent organ damage

Journal of Rheumatology

Volumn 36, Issue 3, 2009, Pages 560-564

  Thamer, Mae ^a   Hernán, Miguel A ^b,c   Zhang, Yi ^a   Cotter, Dennis ^a   Petri, Michelle ^d  

^a Medical Technology and Practice Patterns Institute   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Causal modeling; Corticosteroid treatment; Longterm prednisone therapy; Marginal structural model; Permanent organ damage; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONOTHERAPY; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFORMATION PROCESSING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; POPULATION; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; HOSPITALIZATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; TIME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CHILD; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 65649133584     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080828     Document Type: Article

References (23)

1. Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005;140:205-212 (Pubitemid 40559146)
2. Karlson EW, Daltroy LH, Lew RA, et al. The relationship of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47-56. (Pubitemid 27044035)
3. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-1808 (Pubitemid 30642567)
4. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-1959 (Pubitemid 37075543)
5. Toloza SM, Roseman JM, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004;50:3177-3186
6. Nossent JC. LDICC/ACR damage index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy and prognosis. J Rheumatol 1998;25:654-659 (Pubitemid 28212371)
7. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-625 (Pubitemid 40416916)
8. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the joint effect of non randomized treatments. J Am Stat Assoc 2001;96:440-448 (Pubitemid 33283729)
9. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000;26:199-213.
10. Petri M. Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. Lupus 2005;14:970-973
11. Petri M, Barr SG, Zonana-Nach A, Magder L. Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. J Rheumatol 1999;26:502-503 (Pubitemid 29066765)
12. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-369 (Pubitemid 26085211)
13. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-813 (Pubitemid 27199995)
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640
15. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-625 (Pubitemid 40416916)
16. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560 (Pubitemid 30660034)
17. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 2000;11:561-570 (Pubitemid 30660035)
18. Hernan MA, Brumback B, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 2002;21:1689-1709 (Pubitemid 34678901)
19. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;1:561-570 (Pubitemid 30660035)
20. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177 (Pubitemid 34304256)
21. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol 2002;155:1045-1053 (Pubitemid 34587488)
22. Hernan MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 2002;21:689-1709. (Pubitemid 34678901)
23. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003;158:687-694 (Pubitemid 37175517)